A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0
Key facts
- Who runs it
- Aytu BioPharma, Inc.
- Where
- Cleveland, Houston, Miami, New Orleans, Odessa, and Rochester, United StatesSee the 6 sites
- Trial code
- Status
- Withdrawn
- Started
- Sept 2025
- Ended
- Apr 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- Diagnostic
- Record updated
- 8 March 2024
- Why it stopped
- Study halted prematurely, prior to enrollment of first participant
Who can take part
- Age
- 21 years to 45 years
- Sex
- Men only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Between 21 and 45 years of age, inclusive
- Male at birth
- Sexually abstinent for a minimum of 48 hours
- Sexually abstinent for no more than 7 days
- Provides written informed consent
- Agrees to complete all aspects of the study
Who cannot take part
- Study participant on a previous date
- Surgery in the previous 90 days
- Trauma in the previous 90 days
- Diagnosed and/or is taking chronic medication for a chronic gastrointestinal condition including irritable bowel syndrome, colitis, or similar metabolic dietary conditions
- History of prostate cancer or any cancer that has been active over the last 5 years
- White blood cells and/or round cells are greater than or equal to 1 million sperm/mL
- Diagnosis of azoospermia
- Unable to complete all aspects of the study
- Enrolled in another clinical study at the time of screening
- Vasectomy
- Takes additional daily antioxidant supplements including Vitamin C, Beta-Carotene, Vitamin E, Zinc, N-acetylcysteine, or Selenium. Multivitamin is acceptable for inclusion into the study
- Semen sample does not liquefy in 60 minutes
- Sperm concentration in semen sample is less than 1 million sperm/mL
Where in United States
- Cleveland ClinicCleveland, United States
- Baylor College of MedicineHouston, United States
- University of MiamiMiami, United States
- Tulane UniversityNew Orleans, United States
- Odessa Regional Medical CenterOdessa, United States
- Mayo ClinicRochester, United States
About the trial
What the trial wants to find out
The purpose of this study is to determine if elevations in oxidative stress, as measured by oxidation-reduction potential (ORP), can distinguish between semen samples from men with abnormal semen parameters from those with normal semen parameters. Static ORP (sORP) results, measured by the MiOXSYS System- a novel technology, will be compared to the current World Health Organization (WHO) semen analysis parameters (5th Edition WHO Laboratory Manual for the Examination and Processing of Human Semen [2010]).
The 2 groups in the trial
- Normal Semen
Semen that meet the criteria for "normal" on sperm number, motility, and morphology as described by the current WHO manual.
Treatment: Diagnostic
- Abnormal Semen
Semen that fail to achieve one or more of the criteria for "normal" on sperm number, motility, and morphology as described by the current WHO manual.
Treatment: Diagnostic
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 8 March 2024